Eterna Therapeutics (ERNA)
NASDAQ:ERNA
US Market
Holding ERNA?
Track your performance easily

Eterna Therapeutics (ERNA) Income Statement

215 Followers

Eterna Therapeutics Income Statement

Last quarter (Q ), Eterna Therapeutics's total revenue was $47.00K, an increase of 123.81% from the same quarter last year. In Q, Eterna Therapeutics's net income was $-5.54M. See Eterna Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 141.00K$ 68.00K$ 84.00K$ 84.00K$ 77.00K
Cost of Revenue
$ 342.00K$ 236.00K---
Gross Profit
$ -272.00K$ -168.00K$ 84.00K$ 84.00K$ 77.00K
Operating Expense
$ 21.76M$ 20.51M$ 26.95M$ 113.73M$ 26.49M
Operating Income
$ -21.99M$ -21.14M$ -33.22M$ -113.73M$ -26.49M
Net Non Operating Interest Income Expense
$ -2.20M$ 476.00K$ 30.00K-$ -138.00K
Other Income Expense
$ 106.00K$ -521.00K$ 2.44M$ -899.00K$ 19.28M
Pretax Income
$ -23.93M$ -21.67M$ -24.53M$ -122.48M$ -26.53M
Tax Provision
$ -5.00K$ -3.00K$ 45.00K$ 64.00K$ -322.00K
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
$ -23.91M$ -21.68M$ -24.59M$ -122.56M$ -7.29M
Basic EPS
$ -4.42$ -4.08$ -8.06$ -56.40$ -60.40
Diluted EPS
$ -4.42$ -4.08$ -8.06$ -56.40$ -60.40
Basic Average Shares
$ 21.65M$ 5.31M$ 3.05M$ 2.17M$ 73.00
Diluted Average Shares
$ 21.65M$ 5.31M$ 3.05M$ 2.17M$ 73.00
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
$ 22.15M$ 20.74M$ 26.95M$ 113.73M$ 26.49M
Net Income From Continuing And Discontinued Operation
$ -23.89M$ -21.67M$ -24.58M$ -122.55M$ -7.29M
Normalized Income
$ -18.72M$ -22.06M-$ -90.99M-
Interest Expense
-----
EBIT
$ -22.77M$ -21.06M$ -24.50M$ -122.41M$ -7.25M
EBITDA
$ -19.48M$ -19.93M$ -24.01M$ -121.95M$ -7.15M
Currency in USD

Eterna Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis